Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com
Greylock Partners has raised $500 million to invest exclusively in seed-stage startups. The announcement comes a year after the firm raised $1 billion for its 16th flagship fund to invest in early- and growth-stage tech startups.
Guo and general partner Saam Motamedi said in an interview the fund is part of an expansion of a $1.1 billion fund, which we reported last year, to $1.6 billion, The Information reported. The funding is among the industry’s largest devoted to seed investments, which often represent a startup’s first outside capital.
The pool of funds will give the 56-year-old venture capital firm the ability to write large checks at “lean-in valuations” and emphasize its commitment to early-stage investing, said general partner Sarah Guo. In a thread post on Twitter, Greylock said, “We at @GreylockVC are excited to announce we’ve raised $500M dedicated to seed investing. This is the industry’s largest pool of venture capital dedicated to backing founders at day one.”
#TUBiol5227: Biomarkers & Biotargets: Genetic Testing and Bioethics
Curator: Stephen J. Williams, Ph.D.
The advent of direct to consumer (DTC) genetic testing and the resultant rapid increase in its popularity as well as companies offering such services has created some urgent and unique bioethical challenges surrounding this niche in the marketplace. At first, most DTC companies like 23andMe and Ancestry.com offered non-clinical or non-FDA approved genetic testing as a way for consumers to draw casual inferences from their DNA sequence and existence of known genes that are linked to disease risk, or to get a glimpse of their familial background. However, many issues arose, including legal, privacy, medical, and bioethical issues. Below are some articles which will explain and discuss many of these problems associated with the DTC genetic testing market as well as some alternatives which may exist.
As you can see,this market segment appears to want to expand into the nutritional consulting business as well as targeted biomarkers for specific diseases.
Rising incidence of genetic disorders across the globe will augment the market growth
Increasing prevalence of genetic disorders will propel the demand for direct-to-consumer genetic testing and will augment industry growth over the projected timeline. Increasing cases of genetic diseases such as breast cancer, achondroplasia, colorectal cancer and other diseases have elevated the need for cost-effective and efficient genetic testing avenues in the healthcare market.
For instance, according to the World Cancer Research Fund (WCRF), in 2018, over 2 million new cases of cancer were diagnosed across the globe. Also, breast cancer is stated as the second most commonly occurring cancer. Availability of superior quality and advanced direct-to-consumer genetic testing has drastically reduced the mortality rates in people suffering from cancer by providing vigilant surveillance data even before the onset of the disease. Hence, the aforementioned factors will propel the direct-to-consumer genetic testing market overt the forecast timeline.
Nutrigenomic Testing will provide robust market growth
The nutrigenomic testing segment was valued over USD 220 million market value in 2019 and its market will witness a tremendous growth over 2020-2028. The growth of the market segment is attributed to increasing research activities related to nutritional aspects. Moreover, obesity is another major factor that will boost the demand for direct-to-consumer genetic testing market.
Nutrigenomics testing enables professionals to recommend nutritional guidance and personalized diet to obese people and help them to keep their weight under control while maintaining a healthy lifestyle. Hence, above mentioned factors are anticipated to augment the demand and adoption rate of direct-to-consumer genetic testing through 2028.
Browse key industry insights spread across 161 pages with 126 market data tables & 10 figures & charts from the report, “Direct-To-Consumer Genetic Testing Market Size By Test Type (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomics Testing), By Distribution Channel (Online Platforms, Over-the-Counter), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whole Genome Sequencing (WGS)), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2028” in detail along with the table of contents: https://www.gminsights.com/industry-analysis/direct-to-consumer-dtc-genetic-testing-market
Targeted analysis techniques will drive the market growth over the foreseeable future
Based on technology, the DTC genetic testing market is segmented into whole genome sequencing (WGS), targeted analysis, and single nucleotide polymorphism (SNP) chips. The targeted analysis market segment is projected to witness around 12% CAGR over the forecast period. The segmental growth is attributed to the recent advancements in genetic testing methods that has revolutionized the detection and characterization of genetic codes.
Targeted analysis is mainly utilized to determine any defects in genes that are responsible for a disorder or a disease. Also, growing demand for personalized medicine amongst the population suffering from genetic diseases will boost the demand for targeted analysis technology. As the technology is relatively cheaper, it is highly preferred method used in direct-to-consumer genetic testing procedures. These advantages of targeted analysis are expected to enhance the market growth over the foreseeable future.
Over-the-counter segment will experience a notable growth over the forecast period
The over-the-counter distribution channel is projected to witness around 11% CAGR through 2028. The segmental growth is attributed to the ease in purchasing a test kit for the consumers living in rural areas of developing countries. Consumers prefer over-the-counter distribution channel as they are directly examined by regulatory agencies making it safer to use, thereby driving the market growth over the forecast timeline.
Favorable regulations provide lucrative growth opportunities for direct-to-consumer genetic testing
Europe direct-to-consumer genetic testing market held around 26% share in 2019 and was valued at around USD 290 million. The regional growth is due to elevated government spending on healthcare to provide easy access to genetic testing avenues. Furthermore, European regulatory bodies are working on improving the regulations set on the direct-to-consumer genetic testing methods. Hence, the above-mentioned factors will play significant role in the market growth.
Focus of market players on introducing innovative direct-to-consumer genetic testing devices will offer several growth opportunities
Few of the eminent players operating in direct-to-consumer genetic testing market share include Ancestry, Color Genomics, Living DNA, Mapmygenome, Easy DNA, FamilytreeDNA (Gene By Gene), Full Genome Corporation, Helix OpCo LLC, Identigene, Karmagenes, MyHeritage, Pathway genomics, Genesis Healthcare, and 23andMe. These market players have undertaken various business strategies to enhance their financial stability and help them evolve as leading companies in the direct-to-consumer genetic testing industry.
For example, in November 2018, Helix launched a new genetic testing product, DNA discovery kit, that allows customer to delve into their ancestry. This development expanded the firm’s product portfolio, thereby propelling industry growth in the market.
The following posts discuss bioethical issues related to genetic testing and personalized medicine from a clinicians and scientisit’s perspective
Question:Each of these articles discusses certain bioethical issues although focuses on personalized medicine and treatment. Given your understanding of the robust process involved in validating clinical biomarkers and the current state of the DTC market, how could DTC testing results misinform patients and create mistrust in the physician-patient relationship?
Question: If you are developing a targeted treatment with a companion diagnostic, what bioethical concerns would you address during the drug development process to ensure fair, equitable and ethical treatment of all patients, in trials as well as post market?
Articles on Genetic Testing, Companion Diagnostics and Regulatory Mechanisms
Question: What type of regulatory concerns should one have during the drug development process in regards to use of biomarker testing?From the last article on Protecting Your IP how important is it, as a drug developer, to involve all payers during the drug development process?
Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes
Reporter: Amandeep Kaur, B.Sc., M.Sc.
A recent study reports the development of an advanced AI algorithm which predicts up to five years in advance the starting of type 2 diabetes by utilizing regularly collected medical data. Researchers described their AI model as notable and distinctive based on the specific design which perform assessments at the population level.
The first author Mathieu Ravaut, M.Sc. of the University of Toronto and other team members stated that “The main purpose of our model was to inform population health planning and management for the prevention of diabetes that incorporates health equity. It was not our goal for this model to be applied in the context of individual patient care.”
Research group collected data from 2006 to 2016 of approximately 2.1 million patients treated at the same healthcare system in Ontario, Canada. Even though the patients were belonged to the same area, the authors highlighted that Ontario encompasses a diverse and large population.
The newly developed algorithm was instructed with data of approximately 1.6 million patients, validated with data of about 243,000 patients and evaluated with more than 236,000 patient’s data. The data used to improve the algorithm included the medical history of each patient from previous two years- prescriptions, medications, lab tests and demographic information.
When predicting the onset of type 2 diabetes within five years, the algorithm model reached a test area under the ROC curve of 80.26.
The authors reported that “Our model showed consistent calibration across sex, immigration status, racial/ethnic and material deprivation, and a low to moderate number of events in the health care history of the patient. The cohort was representative of the whole population of Ontario, which is itself among the most diverse in the world. The model was well calibrated, and its discrimination, although with a slightly different end goal, was competitive with results reported in the literature for other machine learning–based studies that used more granular clinical data from electronic medical records without any modifications to the original test set distribution.”
This model could potentially improve the healthcare system of countries equipped with thorough administrative databases and aim towards specific cohorts that may encounter the faulty outcomes.
Research group stated that “Because our machine learning model included social determinants of health that are known to contribute to diabetes risk, our population-wide approach to risk assessment may represent a tool for addressing health disparities.”
Ravaut M, Harish V, Sadeghi H, et al. Development and Validation of a Machine Learning Model Using Administrative Health Data to Predict Onset of Type 2 Diabetes. JAMA Netw Open. 2021;4(5):e2111315. doi:10.1001/jamanetworkopen.2021.11315 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780137
Other related articles were published in this Open Access Online Scientific Journal, including the following:
AI in Drug Discovery: Data Science and Core Biology @Merck &Co, Inc., @GNS Healthcare, @QuartzBio, @Benevolent AI and Nuritas
Reporters: Aviva Lev-Ari, PhD, RN and Irina Robu, PhD
EPISODE #5: WILLIAM MCQUILLAN, FOUNDING PARTNER OF A VENTURE FIRM FOR GLOBALLY AMBITIOUS B2B COMPANIES
William is a founding partner of Frontline Ventures. Prior to starting Frontline, he was a founding employee at Ondra, an award-winning investment boutique that went from a 4 person team to 70+ employees in only 18 months. When Frontline was founded, William was 27 years old, making him the youngest VC ever to have raised a fund at that time (2012). Shortly after recording this episode William announced Frontline Fund III.
In this episode you will learn:
– How William has built a truly differentiated investment thesis for Frontline’s two funds.
– What William looks for in seed stage startups and why he believes integrity is all important and money cannot be the founder’s main driver.
– How William perceives the effects of Brexit and its implications for their investment strategy and work with startups.
– Why William is a supporter of founders taking a small bit of secondaries.
EPISODE #4: SHOMIT GHOSE, GP OF A SILICON VALLEY FIRM WITH 7 FUNDS UNDER ITS BELT
This episode runs contrary to what the European VC stands for and features an American VC from the Valley. However, the focus is on looking from the outside in, as well as carving out lessons learned from decades of collaboration across the Atlantic. Shomit Ghose is a General Partner of ONSET Ventures, a leading early stage venture firm operating out of Sand Hill Road, in Silicon Valley. With more than 130 startups and 7 funds under its belt, ONSET Ventures is a highly respected firm in the Valley. Shomit is a seasoned VC with multiple IPOs under his belt – both as an investor and as an entrepreneur.
In this episode you will learn:
– How the European and American VC landscapes differ and what we can learn from both.
– How to increase your presence and establish collaborations between US and European VCs.
– How to approach building a country-agnostic fund and the role of VCs, LPs and Institutions.
EPISODE #3 MICHAEL HANSEN, CEO OF A LEADING BUSINESS ANGEL ASSOCIATION IN EUROPE
Michael Hansen is the CEO of DanBAN, Denmark’s leading Business Angel Association. DanBAN consist of more than 200 active Angels who collectively invest in more than 30 M€ on an annual basis. Prior to joining DanBAN, Michael was the chief architect behind the sprawling investment environment around the Danish Robotics Cluster which is broadly recognized as one of the very strongest clusters for Robotics companies in Europe, if not the world.
In this episode, you will learn from a true investment cluster builder
– The importance of politicians making brave strategic decisions in promoting cluster development.
– The story of the Danish Robotics Cluster in which the first collaborative robots were hatched, counting with two acquisitions at a valuation of almost 1 billion EUR.
– How to work with national clusters to generate deal flow and fast track deals.
– Collaboration models between Business Angels and VCs.
EPISODE #2 STEPHAN MORAIS, FOUNDER AND MANAGING PARTNER OF A LEADING EARLY-STAGE DEEP TECH VC FIRM
Stephan Morais is the founder and Managing Partner of Indico Capital Partners, a leading early-stage deep tech VC firm. With a diversified background as an investment banker, consultant, entrepreneur and CEO, he has lived in 8 countries and 4 continents over the last 24 years, and acted as and advisor to politicians and European institutions. Prior to founding Indico, Stephan was an Executive Board Member at Caixa Capital, where he led investment rounds of many Portuguese global tech success stories.
In this episode, you’ll learn
– How Stephan tackled raising a VC fund and what to should look for in LPs
– How European VCs can push for policy developments that allow for more capital to be deployed into the industry
– What Europe can learn from other countries and regions
– What learnings Stephan has drawn from running an iberian fund
EPISODE #1 MARC LOHRMANN, MANAGING PARTNER OF A 120 M€ LIFE SCIENCE FUND
Marc Lohrmann is the Managing Partner of Vesalius Biocapital III, a 120 €M venture capital fund investing in late-stage companies in drug development, medical devices, diagnostics and eHealth, across Europe. Prior to joining Vesalius, Marc started eight life sciences companies, worked as an investment manager at a leading corporate VC and worked with several corporate finance boutiques focused on life sciences M&A transactions.
In this episode, you’ll learn
– How VBC III works as a country-agnostic VC fund and the main barriers to more funds investing across Europe.
– How investors without a natural sciences background can create value for Life Sciences companies and why founders find these investors a refreshing element in the board room.
– What Marc would love to change about European VC, what’s important when investing across Europe and what’s next for Marc.
The Davos Agenda 2021 will convene under the theme: A Crucial Year to Rebuild Trust
The World Economic Forum will gather the world’s foremost leaders to address the economic, environmental, social and technological challenges following the COVID-19 pandemic
More than 1,500 business, government and civil society leaders from over 70 countries will set the agenda for a critical year ahead and discuss how to catalyse impact in the rapidly advancing Fourth Industrial Revolution
The conclusions from the Davos Agenda week will feed into task forces working on global issues for the upcoming Special Annual Meeting in Singapore
For more information, please visit http://www.weforum.org; share on social media using the hashtag #DavosAgenda
Geneva, Switzerland, 18 January 2021 – The World Economic Forum Davos Agenda, taking place virtually on 25-29 January, will bring together the foremost leaders of the world to address the new global situation. Heads of state and government, chief executives and leaders from civil society will convene under the theme: A Crucial Year to Rebuild Trust.
The meeting will focus on creating impact, rebuilding trust and shaping the policies and partnerships needed in 2021.
“In the context of the COVID-19 pandemic, the need to reset priorities and the urgency to reform systems have been growing stronger around the world,” said Klaus Schwab, Founder and Executive Chairman of the World Economic Forum. “Rebuilding trust and increasing global cooperation are crucial to fostering innovative and bold solutions to stem the pandemic and drive a robust recovery. This unique meeting will be an opportunity for leaders to outline their vision and address the most important issues of our time, such as the need to accelerate job creation and to protect the environment.”
The COVID-19 pandemic has demonstrated that no institution or individual alone can address the economic, environmental, social and technological challenges of our complex, interdependent world. The pandemic has accelerated systemic changes that were apparent before its inception. The fault lines that emerged in 2020 now appear as critical crossroads in 2021. The Davos Agenda will help leaders choose innovative and bold solutions to stem the pandemic and drive a robust recovery over the next year.
The five programme themes are:
Designing cohesive, sustainable, resilient economic systems (25 January)
Driving responsible industry transformation and growth (26 January)
Enhancing stewardship of the global commons (27 January)
Harnessing the technologies of the Fourth Industrial Revolution (28 January)
Advancing global and regional cooperation (29 January)
Special addresses from G20 heads of state and government and international organizations will provide crucial insights into a range of important issues in the year ahead. Participants will hear first-hand how these public figures will demonstrate leadership and drive action in areas such as the environment, jobs, and advances in innovation brought by the Fourth Industrial Revolution.
Heads of state and government include:
Xi Jinping, President of the People’s Republic of China; Narendra Modi, Prime Minister of India; Yoshihide Suga, Prime Minister of Japan; Emmanuel Macron, President of France; Angela Merkel, Federal Chancellor of Germany; Ursula von der Leyen, President of the European Commission; Giuseppe Conte, Prime Minister of Italy; Moon Jae-in, President of the Republic of Korea; Alberto Fernández, President of Argentina; Cyril Ramaphosa, President of South Africa; Pedro Sánchez, Prime Minister of Spain; Guy Parmelin, President of the Swiss Confederation and Federal Councillor for Economic Affairs, Education and Research; Ivan Duque, President of Colombia; Carlos Alvarado Quesada, President of Costa Rica; Nana Addo Dankwa Akufo-Addo, President of the Republic of Ghana; Kyriakos Mitsotakis, Prime Minister of Greece; Benjamin Netanyahu, Prime Minister of Israel; Abdullah II ibn Al Hussein, King of the Hashemite Kingdom of Jordan; Paul Kagame, President of Rwanda; Lee Hsien Loong, Prime Minister of Singapore, the host of the World Economic Forum Special Annual Meeting 2021.
Other world leaders are expected to confirm.
Leaders from international organizations, government agencies and central banks include:
António Guterres, Secretary-General, United Nations (UN); Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO); Kristalina Georgieva, Managing Director, International Monetary Fund (IMF); Amina Mohammed, Deputy Secretary-General, United Nations (UN); Achim Steiner, Administrator, United Nations Development Programme (UNDP); Phumzile Mlambo-Ngcuka, Undersecretary-General and Executive Director, United Nations Entity for Gender Equality and the Empowerment of Women (UN WOMEN); Dongyu Qu, Director-General, Food and Agriculture Organization of the United Nations (FAO); Inger Andersen, Executive Director, United Nations Environment Programme (UNEP); Henrietta Fore, Executive Director, United Nations Children’s Fund (UNICEF); David Beasley, Executive Director, United Nations World Food Programme (WFP); Fang Liu, Secretary-General, International Civil Aviation Organization (ICAO); Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA; Angel Gurría, Secretary-General, Organisation for Economic Co-operation and Development (OECD); Mauricio Claver-Carone, President, Inter-American Development Bank (IDB); Guy Ryder, Director-General, International Labour Organization (ILO); Jürgen Stock, Secretary-General, International Criminal Police Organization (INTERPOL); Fatih Birol, Executive Director, International Energy Agency (IEA); Rebecca Fatima Sta Maria, Executive Director, APEC Secretariat (Asia-Pacific Economic Cooperation).
Christine Lagarde, President, European Central Bank; François Villeroy de Galhau, Governor of the Central Bank of France; Andrew Bailey, Governor of the Bank of England.
The private sector will be represented by more than 1,000 leaders from the Forum’s member and partner organizations. Seven of the top ten companies by market capitalization are engaged year-round with the Forum and many will participate in The Davos Agenda week. As a working meeting to advance ongoing project work, more than 500 chief executives and chairpersons will take part in sessions throughout the week.
Leaders from civil society are a critical voice in shaping the agenda. Those taking part in the meeting include:
Seth Berkley, Chief Executive Officer, Gavi, the Vaccine Alliance; Gabriela Bucher, Executive Director, Oxfam International; Sharan Burrow, General Secretary, International Trade Union Confederation (ITUC); Hindou Oumarou Ibrahim, President, Association for Indigenous Women and Peoples of Chad (AFPAT); Marco Lambertini, Director-General, WWF International; Laura Liswood, Secretary-General, Council of Women World Leaders; Delia Ferreira Rubio, Chair, Transparency International; Peter Sands, Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria (GF).
The World Economic Forum will release its Global Risks Report 2021 on 19 January. The flagship report is an important marker for prioritizing action in public and private sectors in the year ahead.
The Davos Agenda will also mark the launch of several World Economic Forum initiatives to accelerate the race to net-zero emissions, to champion new standards for racial justice, to ensure artificial intelligence is developed ethically and in the global public interest and to close the digital divide. More details on these initiatives and others will be disclosed at the meeting.
Opening Event and Crystal Awards
The meeting will be preceded by the Opening Event, available on YouTube on Sunday 24 January at 19.00 CET, featuring a welcome from Klaus Schwab and a special address by Guy Parmelin, President of the Swiss Confederation, just before the 27th Crystal Awards hosted by Hilde Schwab, Chairperson and Co-founder, Schwab Foundation for Social Entrepreneurship, and the photographer Platon.
The awards will be followed by the world premiere of “See Me: A Global Concert.” The official programme of The Davos Agenda will begin on 25 January.
In an announcement televised on C-Span, President Elect Joseph Biden announced his new Science Team to advise on science policy matters, as part of the White House Advisory Committee on Science and Technology. Below is a video clip and the transcript, also available at
Venture Summit Virtual Connect West, March 16th -18th 2021 featuring a dedicated Lifesciences / Healthcare Track
Leaders in Pharmaceutical Business Intelligence
&
youngStartup Ventures
UPDATED on 2/17/2021
Venture Summit Virtual Connect West Early Bird rates were extended to this Thursday, February 18th at midnight (EST). Would it be possible to share the dedicated discount code LPBIVIP again with your network? Included updated social media copy below.
The discount code will still operate when the rates increase but applicants should apply asap to lock in the lowest possible rates. Registration closes around March 11th.
Partial roster of over 170 VCs and Angels Confirmed to Speak and Judge:
Bozena Adamczyk, Investment Director, Truffle Capital | Coleman Adams, Partner, CEVG | Dan Altschuler Malek, Managing Partner, Unovis Asset Management | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | Salman Azhar, Founding Partner & Managing Director, Azhar Private Equity | Afonso Babo, Co-managing director, COREangels Impact | Sion Balass, Partner, The Group Ventures | Assaf Barnea, CEO, Sanara Ventures | Hasan Basrai, Associate, Information Venture Partners | Randy Berholtz, Investor Judge, Mesa Verde Venture Partners | Ned Berman, Senior Associate, Differential Ventures | Reetika Bhardwaj, Associate, ARCH Venture Partners | Udit Bhatnagar, Vice President, McRock Capital | Jason Blumberg, CEO/Managing Partner, Energy Foundry | Christopher Booker, Partner, Frist Cressey Ventures | Alice Brooks, Principal, Khosla Ventures | Alex Brufsky, Venture Partner, 1435 Capital | Edouard Bulteau, Principal, Total Carbon Neutrality Ventures | Ryuk Byun, Associate, Aisling Capital | James Carroll, Managing Partner, CC Angel Investments | Adam Carson, Operating Partner, Point72 Ventures | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Andre Chabaneix, Associate, Blue Bear Capital | Iris Chan, Partner, Mighty Capital | Ray Chan, Managing Director, K5 Ventures | Jonathan Charles, Director, Samsung Catalyst Fund | Elizabeth Cho-Fertikh, Co-Founder & Managing Director, MEDA Angels | Ryan Chou, Investment Associate, JetBlue Technology Ventures | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Darren Cooke, Investor and Board Member, Life Science Angels | Amy Coveny, Managing Partner, Quake Capital | Rick Cutright, Technology Principal, OGCI Climate Investments | Joe Darcy, Principal, IDEA Fund Partners | Rahul Daryanani, Investor, Touchdown Ventures | Timur Davis, Principal, Munich Re Ventures | Angelo Del Priore, Partner, HP Tech Ventures | Jun Deng, Investment Partner, Joyance Partners | Eric Desai, Partner, Greenhouse Capital Partners | Philip Deutch, Partner, NGP ETP | Dixon Doll, Co-Founder & Partner Emeritus, DCM Ventures | Francesco Draetta, Principal, Omega Funds | Vikki Dunn, Operating Partner, Energy Innovation Capital | Amy Dyck, Associate, Framework Venture Partners | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Ali Farahanchi, Managing Director, DHVC | Andrew Felbinger, Investor, Urban Innovation Fund | Manny Fernandez, Angel Investor, SF Angels Group | Mark Fields, Partner, Alsop Louie Partners | Carolin Funk, Investment Director, Blue Bear Capital | Tarik Galijasevic, Managing Director, Allstate Strategic Ventures | Elena Gantvarg, Principal, Flint Capital | Chris Garabedian, CEO, Xontogeny | Daisy Garcia, Investment Analyst, JetBlue Technology Ventures | Joe Garcia, Venture Fellow, Rethink Impact | Selma Gasc, Investment Analyst, 360 Capital | Gary Gershony, Founding General Partner, BayMed Venture Partners | Michal Geva, Co-Founder and Managing Partner, Triventures | Shmuel Gniwisch, Managing Partner/Co-founder, Kli Capital | David Goldberg, General Partner, Alpaca VC | Garrett Goldberg, Partner, Bee Partners | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Emi Gonzalez, Senior Principal, Social Starts | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Deepak Gupta, Managing Partner, Blue Bear Ventures | Katie Hayes, Director, Wittington Ventures | Yashwanth Hemaraj, Partner, Benhamou Global Ventures | Thomas Henry, Co-Founder COO, Eunike Ventures | Robert Hess, Angel Investor, Life Science Angels | David Hornik, Partner, August Capital | Kirsten Horning, Principal, XRC Labs | Galit Horovitz, Co-founder, Welltech1 | Conor Hunt, Principal, 1435 Capital | Noel Jee, Principal, Illumina Ventures | Ben Jen, Managing Director, Ben Jen Holdings | Denis Kalyshkin, Principal, I2BF Global Ventures | Tomas Kemtys, Partner, Contrarian Ventures | Hunter Kettering, VC, Red Cedar Ventures | Maureen Klewicki, Investor, Crosscut Ventures | Howard Ko, Principal, Morpheus Ventures | John-Paul Lake, Managing Partner, Kern Venture Group | Rachel Lauren, Analyst, Bertelsmann Digital Media Investments | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Alicia Lenis, Vice President, Chrysalix Venture Capital | Todd Lewis, VP, Prologis Ventures, Prologis Ventures | Ephraim Lindenbaum, Managing Director, Advance Ventures | Charles Ling, Investment Director, Tsingyuan Ventures | Brian Litvak, Market Development, Aster Capital | Jim Lockheed, Principal, JetBlue Technology Ventures | Patrick Lord, Partner – Fintech, Truffle Capital | Eric Lui, Venture Partner, HCG Global Partners | Vincent Lui, Sr. Director Corporate Ventures, SK Telecom Ventures | Shailendra Mahajan, Managing Director, Maxim Ventures | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Radhika Malik, Investment Manager, Samsung Catalyst Fund | Alex Mayall, Associate, Anthemis Group | Melissa McCracken, Principal, Nextech Invest | Maulik Mehta, Investor, Arc Ventures | David Mendez, Managing Partner, Good Growth Capital | Laurie Menoud, Partner, At One Ventures | Inka Mero, Founder & Managing Partner, Voima Ventures | Pedro Mesquita, Investment Analyst, Mindset Ventures | Khash Mohajerani, Director, BWE LLP | Matt Murphy, Partner, Montage Ventures | Olivia Musmanno, Senior Associate, Quake Capital | Molly O’Shea, Investor, NYL Ventures | Gilbert Ohana, Managing Partner, FinTLV Ventures | Victor Orlovski, Managing Partner, Fort Ross Ventures | Shamik Parekh, Investment Associate, Octopus Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Michael Peri, Senior Vice President, NFP Ventures | Michael Perry, Associate, Link Ventures | Daniel Pianko, Managing Director, Achieve Partners | Patricia Poon, Director, Belmond Capital | Robert Poor, Advisor, Good Growth Capital | Ulrich Quay, Managing Partner, BMW i Ventures | Suraj Rajwani, Managing Partner, DoubleRock LLC | Mark Ralph, Executive Director, Boehringer Ingelheim Venture Fund | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Marie-Christine Razaire, Associate, Northwestern Mutual Future Ventures | Julia Reichelstein, Investor, Piva Capital | John Robinson, Partner, Mazarine Ventures | Carolina Rojas, Ventures Analyst, NFP Ventures | Stephen Roland, Associate, Swiftarc Ventures | Alexander Ross, Investment Director, Illuminate Financial | Joseph Rothman, Venture Partner, AlphaPrime Ventures | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Abinav Sankar, Partner, Sopris Capital | Stephanie Sarelakos, VP, Investments, The Venture Collective | Massimo Schäppi, Partner, Tomahawk .VC | Reese Schroeder, Investor, Allstate Strategic Ventures | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Partner, Fort Ross Ventures | Shounok Sinha, Principal, Venture Investing, Constellation Technology Ventures | Michelle Snyder, Partner, McKesson Ventures | Vivek Soni, Venture Partner, S CAP CleanTech | Peter Sopher, Manager, Clean Energy Ventures | Kumar Sripadam, GP, Elevate Capital | Anish Srivastava, Founder & CEO, Vinaj Ventures | Alexander Starchenko, Managing Partner, First Imagine! Ventures | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Ning Sung, Investor, Sandhill Angels | Daniel Teo, Managing Partner, Hunniwell Lake Ventures | Byron Thom, Principal, Framework Venture Partners | Abhinav Tiwari, General Partner, Owl Capital | Erica Van, Investor, Charles River Ventures | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Joe Vasquez, Venture Partner, Revel Partners | Alexander Vavilov, Investment Manager, iTech Capital | Mark Vreeke, Founder, Chemical Angel Network | Jordan Wahbeh, Managing Partner, SV Venture Group | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Isaiah Washington, Analyst, Insight Partners | Lauren Weston, Associate, Thomvest Ventures | Sarah Wolter, Principal, FinTech Collective | Minjia Wu, Principal, SOSV | Yating Xia, Investor, TCL | Steve Yaskin, Venture Partner, Scale Up Ventures | Juan Zavala, Principal, New Markets Venture Partners | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Chen Zhou, Investor, Samsung Catalyst Fund and many more…
Leaders in Pharmaceutical Business Intelligence is pleased to announce its sponsorship and invite you to join us at Venture Summit Virtual Connect West, featuring a dedicated Lifesciences / Healthcare Track
Special offer: 20% off Early Bird Rates (Use discount code “LPBIVIP”)
* Call for Top Innovators Details below
Venture Summit Virtual Connect West
Where Innovation Meets Capital
March 16th -18th 2021
Friends,
Come meet, interact and network online with more than 1,500 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit Virtual Connect West being held virtually on March 16th-18th 2021, featuring a dedicated Lifesciences / Healthcare track.
Whether you’re a Lifesciences /Healthcare startup seeking capital and exposure, or an investor seeking new deals, the Lifesciences / Healthcare track at Venture Summit Virtual Connect West presented by youngStartup Ventures – is the event of the year you won’t want to miss.
A highly productive venture conference, Venture Summit Virtual Connect West will bring together over 1,500 VCs, Corporate VCs, Angel Investors, Industry executives and founders of venture backed, emerging and early stage companies; will feature One-on-One networking (online), more than 150 VCs as speakers/ judges; Venture panels, startup workshops, presentations by more than 100 Top Innovators and Keynotes.
Partial roster of over VCs and Angels confirmed to speak and judge:
Bozena Adamczyk, Investment Director, Truffle Capital | Dan Altschuler Malek, Managing Partner, Unovis Asset Management | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | Sion Balass, Partner, The Group Ventures | Randy Berholtz, Senior Advisor, Mesa Verde Venture Partners | Ned Berman, Senior Associate, Differential Ventures | Udit Bhatnagar, Vice President, McRock Capital | Christopher Booker, Partner, Frist Cressey Ventures | James Carroll, Managing Partner, CC Angel Investments | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Darren Cooke, Investor and Board Member, Life Science Angels | Amy Coveny, Managing Partner, Quake Capital | Joe Darcy, Principal, IDEA Fund Partners | Rahul Daryanani, Investor, Touchdown Ventures | Timur Davis, Principal, Munich Re Ventures | Jun Deng, Investment Partner, Joyance Partners | Philip Deutch, Partner, NGP ETP | Dixon Doll, Co-Founder & Partner Emeritus, DCM Ventures | Vikki Dunn, Operating Partner, Energy Innovation Capital | Amy Dyck, Associate, Framework Venture Partners | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Ali Farahanchi, Managing Director, DHVC | Andrew Felbinger, Investor, Urban Innovation Fund | Mark Fields, Partner, Alsop Louie Partners | Carolin Funk, Investment Director, Blue Bear Capital | Elena Gantvarg, Principal, Flint Capital | Gary Gershony, Founding General Partner, BayMed Venture Partners | David Goldberg, General Partner, Alpaca VC | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Emi Gonzalez, Senior Principal, Social Starts | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Katie Hayes, Director, Wittington Ventures | Robert Hess, Angel Investor, Life Science Angels | Kirsten Horning, Principal, XRC Labs | Ben Jen, Managing Director, Ben Jen Holdings | Hunter Kettering, VC, Red Cedar Ventures | Howard Ko, Principal, Morpheus Ventures | Rachel Lauren, Analyst, Bertelsmann Digital Media Investments | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Alicia Lenis, Vice President, Chrysalix Venture Capital | Todd Lewis, VP, Prologis Ventures, Prologis Ventures | Charles Ling, Investment Director, Tsingyuan Ventures | Jim Lockheed, Principal, JetBlue Technology Ventures | Patrick Lord, Partner – Fintech, Truffle Capital | Eric Lui, Venture Partner, HCG Global Partners | Vincent Lui, Sr. Director Corporate Ventures, SK Telecom Americas | Shailendra Mahajan, Managing Director, Maxim Ventures | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Maulik Mehta, Investor, Arc Ventures | David Mendez, Managing Partner, Good Growth Capital | Laurie Menoud, Partner, At One Ventures | Pedro Mesquita, Investment Analyst, Mindset Ventures | Khash Mohajerani, Director, BWE LLP | Matt Murphy, Partner, Montage Ventures | Molly O’Shea, Investor, NYL Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Daniel Pianko, Managing Director, Achieve Partners | Robert Poor, Advisor, Good Growth Capital | Ulrich Quay, Managing Partner, BMW i Ventures | Suraj Rajwani, Managing Partner, DoubleRock LLC | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Marie-Christine Razaire, Associate, Northwestern Mutual Future Ventures | John Robinson, Partner, Mazarine Ventures | Stephen Roland, Associate, Swiftarc Ventures | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Massimo Schäppi, Partner, Tomahawk .VC | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Partner, Fort Ross Ventures | Michelle Snyder, Partner, McKesson Ventures | Peter Sopher, Manager, Clean Energy Ventures | Kumar Sripadam, GP, Elevate Capital | Anish Srivastava, Founder & CEO, Vinaj Ventures | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Byron Thom, Principal, Framework Venture Partners | Bernhard Ungerbock, Principal, eQventure | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Joe Vasquez, Venture Partner, Revel Partners | Mark Vreeke, Founder, Chemical Angel Network | Jordan Wahbeh, Managing Partner, SV Venture Group | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Lauren Weston, Associate, Thomvest Ventures | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund and many more…
Special Offer:
Leaders in Pharmaceutical Business Intelligence has made special arrangement for our network to receive a unique discount of an additional 20% off the existing “early bird” savings. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.
In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital,and hardcore networking.
Call for TOP INNOVATORS!
Get Noticed > Get Funded > Grow Faster
A select group of more than100Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.
Apply to Present / Nominate a company:
For more information or to be considered for one of the Top Innovatorslots click here.
Seed Pitchfest:
If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click hereto apply for the Seed stage track.
We look forward to seeing you there.
Leaders in Pharmaceutical Business Intelligence& youngStartup Ventures
Leaders in Pharmaceutical Business Intelligence is pleased to announce its sponsorship and invite you to join us at Venture Summit Virtual Connect West, featuring a dedicated Lifesciences / Healthcare Track
Special offer: 20% off Early Bird Rates (Use discount code “LPBIVIP”)
Come meet, interact and network online with more than 1,500 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit Virtual Connect West being held virtually on March 16th-18th 2021, featuring a dedicated Lifesciences / Healthcare track.
Whether you’re a Lifesciences /Healthcare startup seeking capital and exposure, or an investor seeking new deals, the Lifesciences / Healthcare track at Venture Summit Virtual Connect West presented by youngStartup Ventures – is the event of the year you won’t want to miss.
A highly productive venture conference, Venture Summit Virtual Connect West will bring together over 1,500 VCs, Corporate VCs, Angel Investors, Industry executives and founders of venture backed, emerging and early stage companies; will feature One-on-One networking (online), more than 150 VCs as speakers/ judges; Venture panels, startup workshops, presentations by more than 100 Top Innovators and Keynotes.
Partial roster of VCs and Angels confirmed to speak and judge:
Bozena Adamczyk, Investment Director, Truffle Capital | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | James Carroll, Managing Partner, CC Angel Investments | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Timur Davis, Principal, Munich Re Ventures | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Andrew Felbinger, Investor, Urban Innovation Fund | Gary Gershony, Founding General Partner, BayMed Venture Partners | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Kirsten Horning, Principal, XRC Labs | Hunter Kettering, VC, Red Cedar Ventures | Rachel Lauren, Analyst, BDMI | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Matt Murphy, Partner, Montage Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Ratan Singh, Partner, Fort Ross Ventures | Michelle Snyder, Partner, McKesson Ventures | Peter Sopher, Manager, Clean Energy Ventures | Anish Srivastava, Founder & CEO, Vinaj Ventures | Nia Stefani, CEO, Xnergy Financial | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Bernhard Ungerbock, Principal, eQventure | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund and many more…
Special Offer:
Leaders in Pharmaceutical Business Intelligence has made special arrangement for our network to receive a unique discount of an additional 20% off the existing “early bird” savings. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.
In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital,and hardcore networking.
Call for TOP INNOVATORS!
Get Noticed > Get Funded > Grow Faster
A select group of more than100Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.
Apply to Present / Nominate a company:
For more information or to be considered for one of the Top Innovatorslots click here.
Seed Pitchfest:
If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click hereto apply for the Seed stage track.
We look forward to seeing you there.
Leaders in Pharmaceutical Business Intelligence
&
youngStartup Ventures
LinkedIn
Leaders in Pharmaceutical Business Intelligence invites you to join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit Virtual Connect West being held on March 16th– 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.
Whether you are a Lifesciences / Healthcare investor seeking access to new early stage deals, or a CEO or Founder of a new venture looking for funding, visibility and growth, Venture Summit | Virtual Connect is one event you won’t want to miss.
Twitter
Join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit Virtual Connect West being held on March 16th– 18th 2021. Dedicated Lifesciences/Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.
Where do #startups connect with over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators? #VSVC Venture Summit Virtual Connect West being held on March 16th – 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register at http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.
Facebook
Leaders in Pharmaceutical Business Intelligence invites you to join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect West being held on March 16th – 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.
Biomolecular Condensates: A new approach to biology originated @MIT – Drug Discovery at DewPoint Therapeutics, Cambridge, MA gets new leaders, Ameet Nathwani, MD (ex-Sanofi, ex-Novartis) as Chief Executive Officer and Arie Belldegrun, PhD (ex-Kite Therapeutics) on R&D
“The real voyage of discovery consists, not in seeking new landscapes, but in having new eyes.” Marcel Proust
Starting with the study of P granules in C.elegans embryos in 2009, Tony Hyman, working with his collaborators like Frank Julicher, Cliff Brangwynne, Simon Alberti, Mike Rosen, and Rohit Pappu, began to unravel the mysteries of biomolecular condensates. These scientists realized that P granules behave like liquid droplets that form by phase separation (think of oil droplets in salad dressing) and called them condensates.
In subsequent studies, they found to their surprise that many compartments inside cells had the behavior of condensates: they are liquid-like and form by phase separation.
Inspired by the work of Tony and his colleagues, Richard Young, Phillip Sharp, and Arup Chakraborty at MIT applied these approaches to the study of gene expression, similarly shedding light on many important questions in gene control.
Other related article published in this Online Open Access Scientific Journal include:
Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.
Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition
#USAIC20 Dr. Hal Barron, Chief Scientific Officer and President R&D, GlaxoSmithKline GWAS not easy to find which gene drives the association Functional Genomics gene by gene with phenotypes using machine learning significant help
#USAIC20 Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK GWAS not easy to find which gene drives the association Functional Genomics gene by gene with phenotypes using machine learning significant help
#USAIC20 Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Merck & Co. Data on Patients and identification who will benefit fro which therapy cultural bias risk aversion
#USAIC20 Dr. Najat Khan, Chief Operating Officer, Janssen R&D Data Sciences, Johnson & Johnson Data Validation Deployment of algorithms embed data by type early on in the crisis to understand the disease
#USAIC20 Dr. Maya Said, Chief Executive Officer, Outcomes4Me Cancer patients taking change of their care Digital Health – consumerization of Health, patient demand to be part of the decision, part the information FDA launched a Program Project Patient Voice
We’re taking a quick break at #USAIC20 before our next panel on rare diseases starts at 12:20pm EDT. USAIC would like to thank our Sponsors and Partners for supporting this year’s digital event.
#USAIC20 Dr. Roy Vagelos, Chairman of the Board, Regeneron HIV-AIDS: reverse transcriptase converted a lethal disease to a chronic disease, tried hard to make vaccine – the science was not there
#USAIC20 Dr. Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals Congratulates Big Pharma for taking the challenge on COVID-19 Vaccine, Antibody and anti-viral Government funding Merck was independent from Government – to be able to set the price
Christopher Viehbacher, Gurnet Point Capital touches very sensitive topic at #USAIC20 He claims that we are never going to have real innovation out of big pharma! Well this isn’t new but not entirely true either… any more thoughts?
#USAIC20 Christopher Viehbacher, Managing Partner, Gurnet Point Capital Dream of every Biotech – get Big Pharma coming to acquire and pay a lot Morph and adapt
talks about various philosophies and key reasons why certain projects/molecules are killed early. My counter questions- What are chances of losing hope little early? Do small #biopharma publish negative results to aid to the knowledge pool? #USAIC20
#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute COlonorectal cancer is increasing immuno therapy 5 drugs marketed 30% cancer patients are treated early detection key vs metastatic 10% of cancer are inherited treatment early
#USAIC20 Rehan Verjee, President, EMD Serono Charities funding cancer research – were impacted and resources will come later and in decreased amount New opportunities support access to Medicine improve investment across the board
#USAIC20 Dr. Philip Larsen, Global Head of Research, Bayer AG Repurposing drugs as antiviral from drug screening innovating methods Cytokine storm in OCVID-19 – kinase inhibitors may be antiviral data of tested positive allows research of pathway in new ways
#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber 3,000 Telemedicine session in the first week of the Pandemic vs 300 before – patient come back visits patient happy with Telemedicine team virtually need be reimbursed same rate working remotely
#USAIC20 Rehan Verjee, President, EMD Serono entire volume of clinical trials at Roche went down same at EMD delay of 6 month, some were to be initiated but was put on hold Charities funding cancer research were impacted and resources will come later smaller
#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute Dana Farber saw impact of COVID-19 on immunosuppressed patients coming in for Cancer Tx – switch from IV Tx to Oral 96% decrease in screenings due to Pandemic – increase with Cancer
#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Pharma’s obligation for next generations requires investment in R&D vs Politicians running for 4 years Patients must come first vs shareholders vs R&D investment in 2011
#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Antibiotic research at Merck – no market incentives on pricing for Merck to invest in antibiotics people will die from bacterial resistance next pandemic be bacterial
#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Strategies of Merck = “Medicine is for the People not for Profit” – Ketruda in India is not reembureable in India and million are in need it Partnership are encouraged
Chairman Stelios Papadopoulos asks #KennethFrazier if wealthy nations will try to secure large proportion of #COVID19 drugs/vaccines. #KennethFrazie rightly mentions: pharma industry’s responsibility to balance the access to diff countries during pandemic. #USAIC20
Almost 60% participants at #USAIC20 feel that MNCs are more likely to run their #clinicalTrials in #INDIA seeing changing environment here, reveals the poll. Exciting time ahead for scientific fraternity as this can substantially increase the speed of #DrugDevelopment globally
#USAIC20 Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health Vaccine in clinical trials, public need to return for 2nd shot, hesitancy Who will get the Vaccine first in the US most vulnerable of those causing transmission Pharma’s risk
#USAIC20 Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health Testing – PCR expensive does not enable quick testing is expensive result come transmission occurred Antibody testing CRISPR test based Vaccine in clinical trials
#USAIC20 Dr Andrew Plump, President of R&D, Takeda Pharmaceuticals COllaboration effort around the Globe in the Pandemic therapy solutions including Vaccines
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Daniel Menzin
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
komal23ingle
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
satwik Sunnam
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22